Related Experiment Videos
Cancer immunoprevention: tracking down persistent tumor antigens
Pier-Luigi Lollini1, Guido Forni
1Cancer Research Section, Dept of Experimental Pathology, University of Bologna, Viale Filopanti 22, Italy. pierluigi@lollini.dsnet.it
Trends in Immunology
|January 28, 2003
Summary
Identifying novel tumor antigens is key for effective cancer immunoprevention. These antigens must play a critical role in tumor growth and be recognized by both T cells and antibodies, even in variants lacking MHC.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- The immune system can inhibit early tumor development.
- Post-genomic medicine enables identification of at-risk individuals for cancer preventive vaccines.
Purpose of the Study:
- To define criteria for novel tumor antigens crucial for cancer immunoprevention.
- To identify antigens that can overcome immune escape mechanisms.
Main Methods:
- The study outlines criteria for ideal tumor antigens based on pathogenetic role and immune recognition.
- It emphasizes the need for antigens recognized by both T cells and antibodies, even in MHC-loss variants.
Main Results:
- Ideal tumor antigens must have a critical role in tumor progression to prevent antigen-loss variants.
- Antigens must be recognizable by the immune system despite potential immune evasion strategies like MHC loss.
Conclusions:
- The identification of specific tumor antigens is essential for developing effective cancer preventive vaccines.
- These antigens will serve as vital targets for both cancer immunoprevention and immunotherapy.